Redfearn, Isabella Daisy (2026) Inhibiting transforming growth factor-β in pancreatic cancer to encourage vascular normalisation and improve therapeutic response. Masters thesis, York St John University.
Preview |
Text (Masters by Research thesis)
Inhibiting transforming growth factor-β in pancreatic cancer to encourage vascular normalisation and improve therapeutic response.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. | Preview |
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. The most effective treatment is surgery, followed by adjuvant chemotherapy, however this treatment option is only available to 10-20% of patients, and the standard-of-care chemotherapy, gemcitabine, has a 5-year overall survival rate of 31.4%. The PDAC tumour microenvironment is one of the main contributors to poor treatment response, and it is made
up of a dense desmoplastic stroma, caused by cancer-associated fibroblasts, stromal cells that cause fibrosis and produce collagen, contributing to a stiff extracellular matrix. This dense stroma creates a hypoxic environment, with limited and non-functional blood vessels, exhibiting
disorganised lining and leaky structures that impedes drug delivery, increases drug resistance and promotes metastasis. TGF-β is an anti-inflammatory cytokine that has many roles in cancer development including angiogenesis, the formation of new blood vessels. Inhibiting TGF-β has previously been used in other cancers to normalise tumour vasculature, reduce the hypoxic environment, enhance immune cell infiltration and improve drug delivery, however this effect
has not been investigated in PDAC. This study investigates the effect of inhibiting TGF-β on cells and tumour vasculature in pancreatic cancer. PDAC cell lines were used to determine the effect of a TGF-β receptor inhibitor, LY2109671 on cell viability, with inhibition decreasing viability in a dose-dependent manner. Changes in protein and mRNA expression were investigated with TGF-β increasing expression levels of the latent TGF-β, an effect that was inhibited by LY2109671. Fibroblast, and endothelial cells also demonstrated LY2109671 inhibition of TGF-β induced protein and mRNA expression of TGF-β, COL1A1 and bFGF. Finally, LY2109671 was able to reverse the TGF-β-induced suppression of vessel formation in fibroblast and endothelial co cultures. The results of this study highlight a potential treatment option to be used alongside
standard-of-care chemotherapy to improve treatment response in PDAC patients.
| Item Type: | Thesis (Masters) |
|---|---|
| Status: | Published |
| Subjects: | Q Science > Q Science (General) |
| School/Department: | School of Health Sciences |
| URI: | https://ray.yorksj.ac.uk/id/eprint/16248 |
University Staff: Request a correction | RaY Editors: Update this record
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)